A Phase II Study of Eribulin in Recurrent or Refractory Osteosarcoma: a report from the Children’s Oncology Group

BACKGROUND: Patients with recurrent or refractory osteosarcoma have a poor prognosis with less than 30% surviving 2 years. Eribulin is a synthetic analog of halichondrin B, has a novel mechanism of action when compared to other microtubule inhibitors and may have anti-tumor activity in osteosarcoma....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Isakoff, Michael S., Goldsby, Robert, Villaluna, Doojduen, Krailo, Mark D., Hingorani, Pooja, Collier, Anderson, Morris, Carol D., Kolb, E. Anders, Doski, John J., Womer, Richard B., Gorlick, Richard, Janeway, Katherine A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6501793/
https://ncbi.nlm.nih.gov/pubmed/30378256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.27524
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados